Literature DB >> 16115890

Identification of residues responsible for ligand recognition and regioisomeric selectivity of lysophosphatidic acid receptors expressed in mammalian cells.

Yuko Fujiwara1, Vineet Sardar, Akira Tokumura, Daniel Baker, Kimiko Murakami-Murofushi, Abby Parrill, Gabor Tigyi.   

Abstract

The endothelial differentiation gene family encodes three highly homologous G protein-coupled receptors for lysophosphatidic acid (LPA). Based on baculoviral overexpression studies, differences have been proposed in the structure-activity relationship (SAR) of these receptors. We have compared the SAR of the individual receptors either overexpressed transiently at high or at lower levels following stable transfection in LPA-nonresponsive RH7777 cells. The SAR in transfected RH7777 cells was markedly different from that described in insect cells. The LPA(3) receptor has been proposed to be selectively activated by unsaturated LPA species and shows a strong preference for sn-2 versus the sn-1 acyl-LPA regioisomer. Because of the short half-life of sn-2 LPA due to acyl migration under some conditions, we have synthesized acyl migration-resistant analogs using an acetyl group in place of the free hydroxyl group in order to evaluate LPA receptor SAR. Only LPA(1) and LPA(2) showed regioisomeric preference and only for the 18:2 fatty acyl-stabilized LPA sn-1 regioisomer. To identify residues involved in ligand recognition of LPA(3), we developed and validated computational models of LPA(3) complexes with the analogs studied. The models revealed that Arg-3.28 and Gln-3.29 conserved within the LPA-selective endothelial differentiation gene receptors and the more variable Lys-7.35 and Arg-5.38 of LPA(3) form critical interactions with the polar headgroup of LPA. The models identified Leu-2.60 and Val-7.39 of LPA(3) underlying the regioisomer-selective interaction with the acetyl group of the stabilized regioisomers. Mutation of Leu-2.60 to alanine selectively increased the EC(50) of the sn-2 acetyl-LPA regioisomers, whereas alanine replacement of Val-7.39 profoundly affected both regioisomers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16115890     DOI: 10.1074/jbc.M504351200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  Toward the three-dimensional structure and lysophosphatidic acid binding characteristics of the LPA(4)/p2y(9)/GPR23 receptor: a homology modeling study.

Authors:  Guo Li; Philip D Mosier; Xianjun Fang; Yan Zhang
Journal:  J Mol Graph Model       Date:  2009-04-19       Impact factor: 2.518

2.  Identification of non-lipid LPA3 antagonists by virtual screening.

Authors:  James I Fells; Ryoko Tsukahara; Yuko Fujiwara; Jianxiong Liu; Donna H Perygin; Daniel A Osborne; Gabor Tigyi; Abby L Parrill
Journal:  Bioorg Med Chem       Date:  2008-04-18       Impact factor: 3.641

Review 3.  Lysophosphatidic acid type 2 receptor agonists in targeted drug development offer broad therapeutic potential.

Authors:  Gabor J Tigyi; Leonard R Johnson; Sue Chin Lee; Derek D Norman; Erzsebet Szabo; Andrea Balogh; Karin Thompson; Alyssa Boler; W Shannon McCool
Journal:  J Lipid Res       Date:  2019-01-28       Impact factor: 5.922

4.  FTY720 (Gilenya) phosphate selectivity of sphingosine 1-phosphate receptor subtype 1 (S1P1) G protein-coupled receptor requires motifs in intracellular loop 1 and transmembrane domain 2.

Authors:  William J Valentine; Virginia I Godwin; Daniel A Osborne; Jianxiong Liu; Yuko Fujiwara; James Van Brocklyn; Robert Bittman; Abby L Parrill; Gabor Tigyi
Journal:  J Biol Chem       Date:  2011-06-30       Impact factor: 5.157

Review 5.  Aiming drug discovery at lysophosphatidic acid targets.

Authors:  Gabor Tigyi
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

6.  The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury.

Authors:  Wenlin Deng; E Shuyu; Ryoko Tsukahara; William J Valentine; Gangadhar Durgam; Veeresa Gududuru; Louisa Balazs; Venkatraman Manickam; Marcello Arsura; Lester VanMiddlesworth; Leonard R Johnson; Abby L Parrill; Duane D Miller; Gabor Tigyi
Journal:  Gastroenterology       Date:  2007-03-24       Impact factor: 22.682

7.  Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions.

Authors:  Gyöngyi N Kiss; James I Fells; Renuka Gupte; Sue-Chin Lee; Jianxiong Liu; Nóra Nusser; Keng G Lim; Ramesh M Ray; Fang-Tsyr Lin; Abby L Parrill; Balázs Sümegi; Duane D Miller; Gabor Tigyi
Journal:  Mol Pharmacol       Date:  2012-09-11       Impact factor: 4.436

8.  Lysophosphatidic acid-induced arterial wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR.

Authors:  Yunhui Cheng; Natalia Makarova; Ryoko Tsukahara; Huazhang Guo; E Shuyu; Patricia Farrar; Louisa Balazs; Chunxiang Zhang; Gabor Tigyi
Journal:  Cell Signal       Date:  2009-08-23       Impact factor: 4.315

Review 9.  Dissecting influenza virus pathogenesis uncovers a novel chemical approach to combat the infection.

Authors:  Michael B A Oldstone; John R Teijaro; Kevin B Walsh; Hugh Rosen
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

Review 10.  Integrating the puzzle pieces: the current atomistic picture of phospholipid-G protein coupled receptor interactions.

Authors:  Abby L Parrill; Gabor Tigyi
Journal:  Biochim Biophys Acta       Date:  2012-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.